Transdermal patches, those discreet allies we adhere to our skin to release drugs in a controlled manner, have come a long way since their introduction in 1979. While they have multiple advantages, they have not reached the market massively due to the significant challenges that a molecule must overcome to be administered by this route. To highlight this minority participation within the array of means to administer drugs to the body, we can mention that between 2015 and 2022, only 84 transdermal patches were approved out of a total of 7239 generic products by the FDA, representing just 1.2% of these products.